Skip to main content

Peer Review reports

From: The effect of empagliflozin on non-alcoholic fatty liver disease-related parameters in patients with type 2 diabetes mellitus: a randomized controlled trial

Original Submission
24 Dec 2024 Submitted Original manuscript
4 Jan 2025 Author responded Author comments - Fatemeh Shojaei
Resubmission - Version 2
4 Jan 2025 Submitted Manuscript version 2
15 Jan 2025 Reviewed Reviewer Report
22 Jan 2025 Reviewed Reviewer Report - Bryan Adrian Priego-Parra
4 Feb 2025 Author responded Author comments - Fatemeh Shojaei
Resubmission - Version 3
4 Feb 2025 Submitted Manuscript version 3
4 Feb 2025 Author responded Author comments - Fatemeh Shojaei
Resubmission - Version 4
4 Feb 2025 Submitted Manuscript version 4
5 Feb 2025 Reviewed Reviewer Report - Bryan Adrian Priego-Parra
7 Feb 2025 Reviewed Reviewer Report
13 Feb 2025 Author responded Author comments - Fatemeh Shojaei
Resubmission - Version 5
13 Feb 2025 Submitted Manuscript version 5
Publishing
14 Feb 2025 Editorially accepted
26 Feb 2025 Article published 10.1186/s12902-025-01882-8

You can find further information about peer review here.

Back to article page